Headlines about Globus Medical (NYSE:GMED) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Globus Medical earned a news sentiment score of 0.12 on Accern’s scale. Accern also gave press coverage about the medical device company an impact score of 46.3136205693063 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

A number of research firms have weighed in on GMED. Barclays reissued a “sell” rating and set a $36.00 target price on shares of Globus Medical in a report on Wednesday, January 10th. Needham & Company LLC reissued a “hold” rating on shares of Globus Medical in a report on Thursday, November 9th. Piper Jaffray Companies reissued a “buy” rating on shares of Globus Medical in a report on Thursday, October 19th. Zacks Investment Research raised shares of Globus Medical from a “sell” rating to a “hold” rating in a report on Friday, November 10th. Finally, ValuEngine raised shares of Globus Medical from a “hold” rating to a “buy” rating in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the stock. Globus Medical has a consensus rating of “Buy” and an average price target of $40.57.

Shares of Globus Medical (NYSE GMED) opened at $44.60 on Thursday. Globus Medical has a 12 month low of $26.26 and a 12 month high of $47.09. The company has a market cap of $4,302.23, a price-to-earnings ratio of 40.55, a PEG ratio of 2.61 and a beta of 0.48.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Wednesday, November 8th. The medical device company reported $0.30 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.30. Globus Medical had a net margin of 17.54% and a return on equity of 13.67%. The company had revenue of $151.74 million for the quarter, compared to analyst estimates of $150.73 million. During the same period in the prior year, the firm posted $0.29 EPS. The company’s quarterly revenue was up 11.9% on a year-over-year basis. equities analysts predict that Globus Medical will post 1.28 EPS for the current year.

In related news, Director David D. Davidar sold 55,383 shares of the stock in a transaction on Monday, December 4th. The shares were sold at an average price of $40.66, for a total transaction of $2,251,872.78. Following the transaction, the director now directly owns 752,236 shares of the company’s stock, valued at $30,585,915.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Steven Payne sold 3,076 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $39.30, for a total transaction of $120,886.80. Following the transaction, the chief accounting officer now owns 23,847 shares in the company, valued at approximately $937,187.10. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,459 shares of company stock worth $2,947,260. Insiders own 28.21% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Globus Medical (GMED) Getting Somewhat Positive News Coverage, Accern Reports” was reported by Watch List News and is the property of of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.watchlistnews.com/globus-medical-gmed-getting-somewhat-positive-news-coverage-accern-reports/1852247.html.

About Globus Medical

Globus Medical, Inc (Globus) is a medical device company focused on the design, development and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The Company is focused on implants that promote healing in patients with spine disorders. The Company’s products fall into one of two categories: Innovative Fusion or Disruptive Technologies.

Insider Buying and Selling by Quarter for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.